Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

Auteurs : Berghmans T, Remmelink M, Awada A
Année : 2012
Journal : Lung Cancer : Targets and Therapy
Volume : 3
Pages : 91-99